Literature DB >> 25189415

The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.

I Vater1, M Montesinos-Rongen2, M Schlesner3, A Haake1, F Purschke2, R Sprute2, N Mettenmeyer2, I Nazzal2, I Nagel1, J Gutwein1, J Richter1, I Buchhalter3, R B Russell4, O D Wiestler5, R Eils6, M Deckert2, R Siebert1.   

Abstract

To decipher the mutational pattern of primary CNS lymphoma (PCNSL), we performed whole-exome sequencing to a median coverage of 103 × followed by mutation verification in 9 PCNSL and validation using Sanger sequencing in 22 PCNSL. We identified a median of 202 (range: 139-251) potentially somatic single nucleotide variants (SNV) and 14 small indels (range: 7-22) with potentially protein-changing features per PCNSL. Mutations affected the B-cell receptor, toll-like receptor, and NF-κB and genes involved in chromatin structure and modifications, cell-cycle regulation, and immune recognition. A median of 22.2% (range: 20.0-24.7%) of somatic SNVs in 9 PCNSL overlaps with the RGYW motif targeted by somatic hypermutation (SHM); a median of 7.9% (range: 6.2-12.6%) affects its hotspot position suggesting a major impact of SHM on PCNSL pathogenesis. In addition to the well-known targets of aberrant SHM (aSHM) (PIM1), our data suggest new targets of aSHM (KLHL14, OSBPL10, and SUSD2). Among the four most frequently mutated genes was ODZ4 showing protein-changing mutations in 4/9 PCNSL. Together with mutations affecting CSMD2, CSMD3, and PTPRD, these findings may suggest that alterations in genes having a role in CNS development may facilitate diffuse large B-cell lymphoma manifestation in the CNS. This may point to intriguing mechanisms of CNS tropism in PCNSL.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25189415     DOI: 10.1038/leu.2014.264

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  58 in total

Review 1.  Primary lymphoma of the central nervous system: just DLBCL or not?

Authors:  Manuel Montesinos-Rongen; Reiner Siebert; Martina Deckert
Journal:  Blood       Date:  2008-09-18       Impact factor: 22.113

2.  Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes.

Authors:  Jan J Molenaar; Jan Koster; Danny A Zwijnenburg; Peter van Sluis; Linda J Valentijn; Ida van der Ploeg; Mohamed Hamdi; Johan van Nes; Bart A Westerman; Jennemiek van Arkel; Marli E Ebus; Franciska Haneveld; Arjan Lakeman; Linda Schild; Piet Molenaar; Peter Stroeken; Max M van Noesel; Ingrid Ora; Evan E Santo; Huib N Caron; Ellen M Westerhout; Rogier Versteeg
Journal:  Nature       Date:  2012-02-22       Impact factor: 49.962

Review 3.  Regulation of signaling by protein-tyrosine phosphatases: potential roles in the nervous system.

Authors:  C O Arregui; J Balsamo; J Lilien
Journal:  Neurochem Res       Date:  2000-01       Impact factor: 3.996

4.  Differential effects of CXCR4-CXCL12- and CXCR7-CXCL12-mediated immune reactions on murine P0106-125 -induced experimental autoimmune neuritis.

Authors:  A Brunn; O Utermöhlen; M Mihelcic; M Sánchez-Ruiz; M Carstov; T Blau; I Ustinova; M Penfold; M Montesinos-Rongen; M Deckert
Journal:  Neuropathol Appl Neurobiol       Date:  2013-12       Impact factor: 8.090

5.  Mutations in the HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma.

Authors:  Ekaterina S Jordanova; Katja Philippo; Marius J Giphart; Ed Schuuring; Philip M Kluin
Journal:  Immunogenetics       Date:  2003-05-17       Impact factor: 2.846

6.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.

Authors:  David T W Jones; Barbara Hutter; Natalie Jäger; Andrey Korshunov; Marcel Kool; Hans-Jörg Warnatz; Thomas Zichner; Sally R Lambert; Marina Ryzhova; Dong Anh Khuong Quang; Adam M Fontebasso; Adrian M Stütz; Sonja Hutter; Marc Zuckermann; Dominik Sturm; Jan Gronych; Bärbel Lasitschka; Sabine Schmidt; Huriye Seker-Cin; Hendrik Witt; Marc Sultan; Meryem Ralser; Paul A Northcott; Volker Hovestadt; Sebastian Bender; Elke Pfaff; Sebastian Stark; Damien Faury; Jeremy Schwartzentruber; Jacek Majewski; Ursula D Weber; Marc Zapatka; Benjamin Raeder; Matthias Schlesner; Catherine L Worth; Cynthia C Bartholomae; Christof von Kalle; Charles D Imbusch; Sylwester Radomski; Chris Lawerenz; Peter van Sluis; Jan Koster; Richard Volckmann; Rogier Versteeg; Hans Lehrach; Camelia Monoranu; Beate Winkler; Andreas Unterberg; Christel Herold-Mende; Till Milde; Andreas E Kulozik; Martin Ebinger; Martin U Schuhmann; Yoon-Jae Cho; Scott L Pomeroy; Andreas von Deimling; Olaf Witt; Michael D Taylor; Stephan Wolf; Matthias A Karajannis; Charles G Eberhart; Wolfram Scheurlen; Martin Hasselblatt; Keith L Ligon; Mark W Kieran; Jan O Korbel; Marie-Laure Yaspo; Benedikt Brors; Jörg Felsberg; Guido Reifenberger; V Peter Collins; Nada Jabado; Roland Eils; Peter Lichter; Stefan M Pfister
Journal:  Nat Genet       Date:  2013-06-30       Impact factor: 38.330

7.  Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC(low)BCL2 (low) subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas.

Authors:  Anna Brunn; Inga Nagel; Manuel Montesinos-Rongen; Wolfram Klapper; Inga Vater; Werner Paulus; Volkmar Hans; Ingmar Blümcke; Joachim Weis; Reiner Siebert; Martina Deckert
Journal:  Acta Neuropathol       Date:  2013-09-06       Impact factor: 17.088

8.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Nathalie A Johnson; Graham W Slack; Kerry J Savage; Joseph M Connors; Susana Ben-Neriah; Sanja Rogic; David W Scott; King L Tan; Christian Steidl; Laurie H Sehn; Wing C Chan; Javeed Iqbal; Paul N Meyer; Georg Lenz; George Wright; Lisa M Rimsza; Carlo Valentino; Patrick Brunhoeber; Thomas M Grogan; Rita M Braziel; James R Cook; Raymond R Tubbs; Dennis D Weisenburger; Elias Campo; Andreas Rosenwald; German Ott; Jan Delabie; Christina Holcroft; Elaine S Jaffe; Louis M Staudt; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

9.  Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4.

Authors: 
Journal:  Nat Genet       Date:  2011-09-18       Impact factor: 38.330

10.  Mutational analysis of primary central nervous system lymphoma.

Authors:  Aurélie Bruno; Blandine Boisselier; Karim Labreche; Yannick Marie; Marc Polivka; Anne Jouvet; Clovis Adam; Dominique Figarella-Branger; Catherine Miquel; Sandrine Eimer; Caroline Houillier; Carole Soussain; Karima Mokhtari; Romain Daveau; Khê Hoang-Xuan
Journal:  Oncotarget       Date:  2014-07-15
View more
  52 in total

1.  Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.

Authors:  Christian Grommes; Alessandro Pastore; Nicolaos Palaskas; Sarah S Tang; Carl Campos; Derrek Schartz; Paolo Codega; Donna Nichol; Owen Clark; Wan-Ying Hsieh; Dan Rohle; Marc Rosenblum; Agnes Viale; Viviane S Tabar; Cameron W Brennan; Igor T Gavrilovic; Thomas J Kaley; Craig P Nolan; Antonio Omuro; Elena Pentsova; Alissa A Thomas; Elina Tsyvkin; Ariela Noy; M Lia Palomba; Paul Hamlin; Craig S Sauter; Craig H Moskowitz; Julia Wolfe; Ahmet Dogan; Minhee Won; Jon Glass; Scott Peak; Enrico C Lallana; Vaios Hatzoglou; Anne S Reiner; Philip H Gutin; Jason T Huse; Katherine S Panageas; Thomas G Graeber; Nikolaus Schultz; Lisa M DeAngelis; Ingo K Mellinghoff
Journal:  Cancer Discov       Date:  2017-06-15       Impact factor: 39.397

Review 2.  Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment.

Authors:  Ryan M Young; James D Phelan; Wyndham H Wilson; Louis M Staudt
Journal:  Immunol Rev       Date:  2019-09       Impact factor: 12.988

3.  Branched clonal evolution: nodal follicular lymphoma and primary diffuse large B-cell lymphoma of the central nervous system.

Authors:  Gilberto I Barranco; Sara Fernández; Raquel Oña; Julia González-Rincón; Angel Martínez-Ramírez; Ana Teijo; Francisca I Camacho; Fernando J Pinedo; Margarita Sánchez-Beato; Lucia Pedrosa; Adolfo de la Fuente; Mónica Estévez; Rebeca Iglesias; Carlos Montalbán; Juan F García
Journal:  Haematologica       Date:  2019-03-19       Impact factor: 9.941

4.  Identifying targetable genetic features in primary CNS lymphoma.

Authors:  Agnieszka Korfel; Uwe Schlegel
Journal:  Int J Hematol Oncol       Date:  2017-01-13

5.  Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma.

Authors:  Christian Grommes; James L Rubenstein; Lisa M DeAngelis; Andres J M Ferreri; Tracy T Batchelor
Journal:  Neuro Oncol       Date:  2019-02-19       Impact factor: 12.300

6.  Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens.

Authors:  Ryan M Young; Tianyi Wu; Roland Schmitz; Moez Dawood; Wenming Xiao; James D Phelan; Weihong Xu; Laurence Menard; Eric Meffre; Wing-Chung C Chan; Elaine S Jaffe; Randy D Gascoyne; Elías Campo; Andreas Rosenwald; German Ott; Jan Delabie; Lisa M Rimsza; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-19       Impact factor: 11.205

Review 7.  Liquid biopsy in lymphoma: Molecular methods and clinical applications.

Authors:  Melita Cirillo; Alexander F M Craig; Sven Borchmann; David M Kurtz
Journal:  Cancer Treat Rev       Date:  2020-09-22       Impact factor: 12.111

8.  MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome.

Authors:  ZhiJun Qiu; An-Ping Lin; Shoulei Jiang; Sara M Elkashef; Jamie Myers; Subramanya Srikantan; Binu Sasi; John Z Cao; Lucy A Godley; Dinesh Rakheja; Yingli Lyu; Siyuan Zheng; Muniswamy Madesh; Yuzuru Shiio; Patricia L M Dahia; Ricardo C T Aguiar
Journal:  Cell Chem Biol       Date:  2020-02-25       Impact factor: 8.116

9.  [Primary vitreoretinal lymphoma].

Authors:  D Jaehne; S E Coupland
Journal:  Ophthalmologe       Date:  2018-04       Impact factor: 1.059

10.  EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.

Authors:  M K Gandhi; T Hoang; S C Law; S Brosda; K O'Rourke; J W D Tobin; F Vari; V Murigneux; L Fink; J Gunawardana; C Gould; H Oey; K Bednarska; S Delecluse; R U Trappe; L Merida de Long; M B Sabdia; G Bhagat; G Hapgood; E Blyth; L Clancy; J Wight; E Hawkes; L M Rimsza; A Maguire; K Bojarczuk; B Chapuy; C Keane
Journal:  Blood       Date:  2021-03-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.